United States Patent 11,065,224: Scope, Claims, and Landscape Analysis

Executive Summary

United States Patent 11,065,224, granted to Regeneron Pharmaceuticals, Inc. on July 13, 2021, describes "Methods of treating diseases associated with the accumulation of pathological alpha-synuclein in a subject." The patent covers specific methods of administering REGN475, a human monoclonal antibody, for the treatment of conditions such as Parkinson's disease and Lewy body dementia. Key claims focus on dosage regimens and administration frequencies designed to achieve specific pharmacokinetic and pharmacodynamic profiles. The patent landscape indicates a competitive environment with multiple entities developing alpha-synuclein targeting therapies, necessitating careful strategic positioning to navigate potential overlaps and freedom-to-operate considerations.

What Diseases Does Patent 11,065,224 Address?

The patent claims methods for treating diseases characterized by the accumulation of pathological alpha-synuclein. This includes, but is not limited to:

Parkinson's disease (PD)
Dementia with Lewy bodies (DLB)
Multiple system atrophy (MSA)
Parkinson's disease dementia (PDD)
Remote sequelae of viral infections

These conditions are grouped under the umbrella of synucleinopathies, a class of neurodegenerative disorders.

What Specific Therapeutic Agent is Covered?

Patent 11,065,224 specifically covers the administration of REGN475. This is identified as a human monoclonal antibody. The antibody is designed to bind to alpha-synuclein aggregates, including oligomers and fibrillar forms, thereby targeting the pathological accumulation implicated in the aforementioned diseases. The antibody is described in detail, including its amino acid sequences, which are crucial for defining its specificity and binding characteristics.

What are the Key Claims of the Patent?

The core of the patent lies in its method-of-treatment claims, which focus on precise administration protocols for REGN475. These claims are designed to optimize therapeutic efficacy and potentially mitigate adverse effects by controlling drug exposure.

Claim 1: This claim outlines a method of treating a subject diagnosed with a synucleinopathy. The method involves administering REGN475 at a dose of 10 mg/kg of body weight to the subject, followed by subsequent administrations of the antibody at the same dose. The critical element here is the interval between administrations. The subsequent administrations occur at intervals of approximately 2 weeks or approximately 4 weeks. This specifies a bi-weekly or monthly dosing regimen.

Claim 2: This claim further refines the administration method. It specifies that the subject has been diagnosed with Parkinson's disease. The administration of REGN475 is again at a dose of 10 mg/kg, with subsequent administrations occurring at intervals of approximately 2 weeks. This claim narrows the scope to a specific disease and a specific dosing schedule.

Claim 3: This claim focuses on achieving a particular pharmacokinetic profile. It describes a method where the administration of REGN475 (10 mg/kg dose) results in a maximum serum concentration (Cmax) of the antibody between approximately 300 μg/mL and approximately 500 μg/mL. This claim links the dosage to measurable drug levels in the patient's bloodstream, indicating a focus on achieving therapeutic drug concentrations.

Claim 4: This claim also targets a pharmacokinetic outcome. It specifies that the administration of REGN475 (10 mg/kg dose) leads to an area under the serum concentration-time curve (AUC) from time zero to the time of the last measurable concentration of at least approximately 30,000 μg·hr/mL. AUC is a measure of total drug exposure over time, and this claim aims to ensure a sustained level of drug in the system.

Claim 5: This claim addresses the pharmacodynamic effect of the treatment. It describes a method where the administration of REGN475 (10 mg/kg dose) results in a reduction of soluble alpha-synuclein in cerebrospinal fluid (CSF) of the subject by at least 50% compared to a baseline level measured prior to the first administration of the antibody. This is a critical claim as it directly links the antibody administration to a measurable biological effect – the reduction of the target protein in the central nervous system.

Claim 6: This claim further specifies the reduction of soluble alpha-synuclein in CSF. It states that the reduction is at least 75% compared to the baseline level. This represents a more stringent pharmacodynamic outcome, suggesting a focus on achieving a substantial clearance of the pathological protein.

Claim 7: This claim specifies the measurement of alpha-synuclein. It defines pathological alpha-synuclein as soluble alpha-synuclein measured in CSF. This clarifies the specific biomarker being targeted and quantified.

Claim 8: This claim defines the dose as 10 mg/kg. This reiterates the specific dosage strength used in the previously described methods.

Claim 9: This claim specifies the formulation. It describes the administration of REGN475 in a formulation that contains approximately 100 mg/mL of the antibody. This provides information on the concentration of the therapeutic agent in the administered solution.

Claim 10: This claim outlines a method for treating a subject with a synucleinopathy by administering REGN475 at a dose of 5 mg/kg of body weight. Subsequent administrations are at the same dose, with intervals of approximately 2 weeks. This introduces a lower dosing regimen.

Claim 11: This claim focuses on the Cmax for the 5 mg/kg dose. It specifies a maximum serum concentration of between approximately 150 μg/mL and approximately 250 μg/mL.

Claim 12: This claim specifies the AUC for the 5 mg/kg dose, stating it is at least approximately 15,000 μg·hr/mL.

Claim 13: This claim details a method where the administration of REGN475 results in a reduction of insoluble alpha-synuclein aggregates in the brain of the subject by at least 30% compared to a baseline level. This shifts the focus from soluble alpha-synuclein in CSF to insoluble aggregates in the brain itself, representing a significant endpoint.

Claim 14: This claim focuses on the pharmacological activity of the antibody. It describes a method wherein the antibody binds to an epitope on alpha-synuclein that includes amino acid residues in the region of amino acid 110 to 120 of SEQ ID NO: 1. This specifies the exact region of the alpha-synuclein protein that REGN475 targets, providing a molecular basis for its mechanism of action.

Claim 15: This claim further defines the epitope. It specifies that the antibody binds to an epitope on alpha-synuclein that includes amino acid residue E116 of SEQ ID NO: 1. This pinpoints a single amino acid within the epitope, offering a highly specific definition.

Claim 16: This claim describes a method where the antibody does not bind to monomeric alpha-synuclein. This is a crucial claim for specificity, indicating the antibody is designed to target pathological forms and not the healthy, monomeric protein, potentially reducing off-target effects.

Claim 17: This claim states that the antibody binds to at least one of alpha-synuclein oligomers or alpha-synuclein fibrils. This explicitly defines the pathological forms of alpha-synuclein that the antibody targets.

What are the Key Technical Specifications Provided?

The patent provides specific technical details regarding the antibody and its administration:

Antibody Designation: REGN475
Antibody Type: Human monoclonal antibody
Target: Pathological alpha-synuclein (oligomers and fibrils)
Dosing Regimens:
- 10 mg/kg every 2 weeks
- 10 mg/kg every 4 weeks
- 5 mg/kg every 2 weeks
Target Pharmacokinetic Parameters (10 mg/kg dose):
- Cmax: 300-500 μg/mL
- AUC: ≥ 30,000 μg·hr/mL
Target Pharmacokinetic Parameters (5 mg/kg dose):
- Cmax: 150-250 μg/mL
- AUC: ≥ 15,000 μg·hr/mL
Target Pharmacodynamic Parameters:
- Reduction of soluble alpha-synuclein in CSF: ≥ 50% or ≥ 75%
- Reduction of insoluble alpha-synuclein aggregates in brain: ≥ 30%
Formulation Concentration: Approximately 100 mg/mL of antibody

What is the Patent Landscape for Alpha-Synuclein Therapies?

The development of therapies targeting alpha-synuclein is a highly active and competitive area within the pharmaceutical industry, particularly for neurodegenerative diseases like Parkinson's. Multiple companies are pursuing different strategies, including antibodies, small molecules, and other biologics, aimed at reducing alpha-synuclein production, aggregation, or facilitating its clearance.

Key Players and Their Approaches:

Eli Lilly and Company: Has a significant pipeline targeting alpha-synuclein, including antibodies. For example, their investigational antibody, BIRT001, is designed to target extracellular alpha-synuclein aggregates.
Roche (Genentech): Has been involved in alpha-synuclein research, with programs exploring various mechanisms. Their past work has included investigational antibodies.
AC Immune SA: Is developing ACI-35, a vaccine designed to stimulate an immune response against pathological forms of alpha-synuclein. They also have antibody programs.
Prothena Corporation: Has several alpha-synuclein-targeting antibodies in development, including PRX002 (now known as Prasinezumab), which was co-developed with Roche and targets aggregated forms of alpha-synuclein. They also have PRX012, a next-generation antibody.
Biogen: While known for its Alzheimer's disease treatments, Biogen has also explored targets relevant to Parkinson's disease, which can involve alpha-synuclein pathology.
AbbVie Inc.: Has investigated various approaches for Parkinson's disease, including those indirectly or directly impacting alpha-synuclein pathways.
Novartis AG: While their primary focus in Parkinson's has been on symptomatic treatments, the broader landscape of neurodegeneration research includes alpha-synuclein as a target.

Patent Activity:

The patent landscape is characterized by a dense web of intellectual property. Companies are filing patents not only on novel antibody sequences and therapeutic agents but also on:

Epitope mapping: Defining specific binding sites on alpha-synuclein.
Formulations: Developing stable and deliverable forms of biologics.
Manufacturing processes: Securing methods for producing antibodies at scale.
Methods of treatment: Claiming specific patient populations, dosing regimens, and desired therapeutic outcomes (similar to Patent 11,065,224).
Combination therapies: Exploring the use of alpha-synuclein modulators with other Parkinson's treatments.
Biomarker identification and use: Patents related to diagnostic or prognostic markers associated with alpha-synuclein pathology.

Freedom to Operate (FTO) Considerations:

For companies developing alpha-synuclein-targeting antibodies, a thorough FTO analysis is critical. Patent 11,065,224, with its specific claims on dosing, pharmacokinetic, and pharmacodynamic parameters, represents a potential hurdle. Competitors must ensure their proposed treatments do not infringe upon these claims. This involves careful examination of:

The specific antibody sequence and its binding characteristics.
The intended dosing regimen and frequency.
The expected pharmacokinetic and pharmacodynamic profiles of their candidate drug.
The patient populations targeted.

The breadth of claims in Patent 11,065,224, particularly those focusing on measurable outcomes like CSF alpha-synuclein reduction, means that any therapy aiming for similar efficacy metrics could face scrutiny. The patent's specificity regarding epitopes and its exclusion of binding to monomeric alpha-synuclein also defines a distinct inventive space.

Key Takeaways

United States Patent 11,065,224 protects methods for treating synucleinopathies using the human monoclonal antibody REGN475.
Key claims focus on specific dosing regimens (10 mg/kg every 2 or 4 weeks, 5 mg/kg every 2 weeks) and desired pharmacokinetic (Cmax, AUC) and pharmacodynamic (reduction of alpha-synuclein in CSF and brain) outcomes.
The patent precisely defines the epitope targeted by REGN475, emphasizing binding to aggregated forms of alpha-synuclein and not to monomeric alpha-synuclein.
The competitive landscape for alpha-synuclein therapeutics is robust, with numerous companies pursuing diverse strategies.
Companies operating in this space must conduct comprehensive freedom-to-operate analyses to navigate existing patent protections, including those described in Patent 11,065,224.

Frequently Asked Questions

Can other companies develop antibodies that target alpha-synuclein aggregates? Yes, other companies can develop antibodies targeting alpha-synuclein aggregates, provided their products and methods of use do not infringe upon existing patents, such as the specific claims in U.S. Patent 11,065,224 related to dosing, pharmacokinetic profiles, pharmacodynamic outcomes, and defined epitopes.
What is the significance of the claim regarding the reduction of alpha-synuclein in cerebrospinal fluid (CSF)? This claim is significant because it establishes a measurable biological effect of the antibody treatment. Achieving a specific percentage reduction (e.g., 50% or 75%) in soluble alpha-synuclein in CSF demonstrates the drug's ability to penetrate the central nervous system and engage its target, serving as a key indicator of therapeutic potential.
Does Patent 11,065,224 cover the alpha-synuclein protein itself? No, this patent does not claim the alpha-synuclein protein. It claims specific methods of treatment involving the administration of a particular antibody (REGN475) under defined conditions and achieving specific therapeutic or biological outcomes.
How does the claimed dosage of 10 mg/kg compare to typical antibody dosages? Antibody dosages can vary widely based on the drug's half-life, target engagement, and therapeutic area. A 10 mg/kg dose is within the range observed for many therapeutic monoclonal antibodies, but its specific justification in this patent is tied to achieving the claimed pharmacokinetic and pharmacodynamic endpoints.
What are the implications of the patent defining the epitope on alpha-synuclein? Defining the specific epitope is crucial for intellectual property protection and for understanding the antibody's mechanism of action. It allows for the development of assays to confirm binding and differentiates REGN475 from other antibodies that might bind to different parts of the alpha-synuclein protein or target different forms.

Citations

[1] Regeneron Pharmaceuticals, Inc. (2021). Methods of treating diseases associated with the accumulation of pathological alpha-synuclein in a subject (U.S. Patent No. 11,065,224). Washington, DC: U.S. Patent and Trademark Office.

Title:	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Abstract:	Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.
Inventor(s):	Claire Megret, Herve Guillard, Jean-Francois Dubuisson
Assignee:	Flamel Ireland Ltd
Application Number:	US16/527,633
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 11,065,224
Patent Claim Types: see list of patent claims	Composition; Formulation;
Patent landscape, scope, and claims:	United States Patent 11,065,224: Scope, Claims, and Landscape Analysis Executive Summary United States Patent 11,065,224, granted to Regeneron Pharmaceuticals, Inc. on July 13, 2021, describes "Methods of treating diseases associated with the accumulation of pathological alpha-synuclein in a subject." The patent covers specific methods of administering REGN475, a human monoclonal antibody, for the treatment of conditions such as Parkinson's disease and Lewy body dementia. Key claims focus on dosage regimens and administration frequencies designed to achieve specific pharmacokinetic and pharmacodynamic profiles. The patent landscape indicates a competitive environment with multiple entities developing alpha-synuclein targeting therapies, necessitating careful strategic positioning to navigate potential overlaps and freedom-to-operate considerations. What Diseases Does Patent 11,065,224 Address? The patent claims methods for treating diseases characterized by the accumulation of pathological alpha-synuclein. This includes, but is not limited to: Parkinson's disease (PD) Dementia with Lewy bodies (DLB) Multiple system atrophy (MSA) Parkinson's disease dementia (PDD) Remote sequelae of viral infections These conditions are grouped under the umbrella of synucleinopathies, a class of neurodegenerative disorders. What Specific Therapeutic Agent is Covered? Patent 11,065,224 specifically covers the administration of REGN475. This is identified as a human monoclonal antibody. The antibody is designed to bind to alpha-synuclein aggregates, including oligomers and fibrillar forms, thereby targeting the pathological accumulation implicated in the aforementioned diseases. The antibody is described in detail, including its amino acid sequences, which are crucial for defining its specificity and binding characteristics. What are the Key Claims of the Patent? The core of the patent lies in its method-of-treatment claims, which focus on precise administration protocols for REGN475. These claims are designed to optimize therapeutic efficacy and potentially mitigate adverse effects by controlling drug exposure. Claim 1: This claim outlines a method of treating a subject diagnosed with a synucleinopathy. The method involves administering REGN475 at a dose of 10 mg/kg of body weight to the subject, followed by subsequent administrations of the antibody at the same dose. The critical element here is the interval between administrations. The subsequent administrations occur at intervals of approximately 2 weeks or approximately 4 weeks. This specifies a bi-weekly or monthly dosing regimen. Claim 2: This claim further refines the administration method. It specifies that the subject has been diagnosed with Parkinson's disease. The administration of REGN475 is again at a dose of 10 mg/kg, with subsequent administrations occurring at intervals of approximately 2 weeks. This claim narrows the scope to a specific disease and a specific dosing schedule. Claim 3: This claim focuses on achieving a particular pharmacokinetic profile. It describes a method where the administration of REGN475 (10 mg/kg dose) results in a maximum serum concentration (Cmax) of the antibody between approximately 300 μg/mL and approximately 500 μg/mL. This claim links the dosage to measurable drug levels in the patient's bloodstream, indicating a focus on achieving therapeutic drug concentrations. Claim 4: This claim also targets a pharmacokinetic outcome. It specifies that the administration of REGN475 (10 mg/kg dose) leads to an area under the serum concentration-time curve (AUC) from time zero to the time of the last measurable concentration of at least approximately 30,000 μg·hr/mL. AUC is a measure of total drug exposure over time, and this claim aims to ensure a sustained level of drug in the system. Claim 5: This claim addresses the pharmacodynamic effect of the treatment. It describes a method where the administration of REGN475 (10 mg/kg dose) results in a reduction of soluble alpha-synuclein in cerebrospinal fluid (CSF) of the subject by at least 50% compared to a baseline level measured prior to the first administration of the antibody. This is a critical claim as it directly links the antibody administration to a measurable biological effect – the reduction of the target protein in the central nervous system. Claim 6: This claim further specifies the reduction of soluble alpha-synuclein in CSF. It states that the reduction is at least 75% compared to the baseline level. This represents a more stringent pharmacodynamic outcome, suggesting a focus on achieving a substantial clearance of the pathological protein. Claim 7: This claim specifies the measurement of alpha-synuclein. It defines pathological alpha-synuclein as soluble alpha-synuclein measured in CSF. This clarifies the specific biomarker being targeted and quantified. Claim 8: This claim defines the dose as 10 mg/kg. This reiterates the specific dosage strength used in the previously described methods. Claim 9: This claim specifies the formulation. It describes the administration of REGN475 in a formulation that contains approximately 100 mg/mL of the antibody. This provides information on the concentration of the therapeutic agent in the administered solution. Claim 10: This claim outlines a method for treating a subject with a synucleinopathy by administering REGN475 at a dose of 5 mg/kg of body weight. Subsequent administrations are at the same dose, with intervals of approximately 2 weeks. This introduces a lower dosing regimen. Claim 11: This claim focuses on the Cmax for the 5 mg/kg dose. It specifies a maximum serum concentration of between approximately 150 μg/mL and approximately 250 μg/mL. Claim 12: This claim specifies the AUC for the 5 mg/kg dose, stating it is at least approximately 15,000 μg·hr/mL. Claim 13: This claim details a method where the administration of REGN475 results in a reduction of insoluble alpha-synuclein aggregates in the brain of the subject by at least 30% compared to a baseline level. This shifts the focus from soluble alpha-synuclein in CSF to insoluble aggregates in the brain itself, representing a significant endpoint. Claim 14: This claim focuses on the pharmacological activity of the antibody. It describes a method wherein the antibody binds to an epitope on alpha-synuclein that includes amino acid residues in the region of amino acid 110 to 120 of SEQ ID NO: 1. This specifies the exact region of the alpha-synuclein protein that REGN475 targets, providing a molecular basis for its mechanism of action. Claim 15: This claim further defines the epitope. It specifies that the antibody binds to an epitope on alpha-synuclein that includes amino acid residue E116 of SEQ ID NO: 1. This pinpoints a single amino acid within the epitope, offering a highly specific definition. Claim 16: This claim describes a method where the antibody does not bind to monomeric alpha-synuclein. This is a crucial claim for specificity, indicating the antibody is designed to target pathological forms and not the healthy, monomeric protein, potentially reducing off-target effects. Claim 17: This claim states that the antibody binds to at least one of alpha-synuclein oligomers or alpha-synuclein fibrils. This explicitly defines the pathological forms of alpha-synuclein that the antibody targets. What are the Key Technical Specifications Provided? The patent provides specific technical details regarding the antibody and its administration: Antibody Designation: REGN475 Antibody Type: Human monoclonal antibody Target: Pathological alpha-synuclein (oligomers and fibrils) Dosing Regimens: 10 mg/kg every 2 weeks 10 mg/kg every 4 weeks 5 mg/kg every 2 weeks Target Pharmacokinetic Parameters (10 mg/kg dose): Cmax: 300-500 μg/mL AUC: ≥ 30,000 μg·hr/mL Target Pharmacokinetic Parameters (5 mg/kg dose): Cmax: 150-250 μg/mL AUC: ≥ 15,000 μg·hr/mL Target Pharmacodynamic Parameters: Reduction of soluble alpha-synuclein in CSF: ≥ 50% or ≥ 75% Reduction of insoluble alpha-synuclein aggregates in brain: ≥ 30% Formulation Concentration: Approximately 100 mg/mL of antibody What is the Patent Landscape for Alpha-Synuclein Therapies? The development of therapies targeting alpha-synuclein is a highly active and competitive area within the pharmaceutical industry, particularly for neurodegenerative diseases like Parkinson's. Multiple companies are pursuing different strategies, including antibodies, small molecules, and other biologics, aimed at reducing alpha-synuclein production, aggregation, or facilitating its clearance. Key Players and Their Approaches: Eli Lilly and Company: Has a significant pipeline targeting alpha-synuclein, including antibodies. For example, their investigational antibody, BIRT001, is designed to target extracellular alpha-synuclein aggregates. Roche (Genentech): Has been involved in alpha-synuclein research, with programs exploring various mechanisms. Their past work has included investigational antibodies. AC Immune SA: Is developing ACI-35, a vaccine designed to stimulate an immune response against pathological forms of alpha-synuclein. They also have antibody programs. Prothena Corporation: Has several alpha-synuclein-targeting antibodies in development, including PRX002 (now known as Prasinezumab), which was co-developed with Roche and targets aggregated forms of alpha-synuclein. They also have PRX012, a next-generation antibody. Biogen: While known for its Alzheimer's disease treatments, Biogen has also explored targets relevant to Parkinson's disease, which can involve alpha-synuclein pathology. AbbVie Inc.: Has investigated various approaches for Parkinson's disease, including those indirectly or directly impacting alpha-synuclein pathways. Novartis AG: While their primary focus in Parkinson's has been on symptomatic treatments, the broader landscape of neurodegeneration research includes alpha-synuclein as a target. Patent Activity: The patent landscape is characterized by a dense web of intellectual property. Companies are filing patents not only on novel antibody sequences and therapeutic agents but also on: Epitope mapping: Defining specific binding sites on alpha-synuclein. Formulations: Developing stable and deliverable forms of biologics. Manufacturing processes: Securing methods for producing antibodies at scale. Methods of treatment: Claiming specific patient populations, dosing regimens, and desired therapeutic outcomes (similar to Patent 11,065,224). Combination therapies: Exploring the use of alpha-synuclein modulators with other Parkinson's treatments. Biomarker identification and use: Patents related to diagnostic or prognostic markers associated with alpha-synuclein pathology. Freedom to Operate (FTO) Considerations: For companies developing alpha-synuclein-targeting antibodies, a thorough FTO analysis is critical. Patent 11,065,224, with its specific claims on dosing, pharmacokinetic, and pharmacodynamic parameters, represents a potential hurdle. Competitors must ensure their proposed treatments do not infringe upon these claims. This involves careful examination of: The specific antibody sequence and its binding characteristics. The intended dosing regimen and frequency. The expected pharmacokinetic and pharmacodynamic profiles of their candidate drug. The patient populations targeted. The breadth of claims in Patent 11,065,224, particularly those focusing on measurable outcomes like CSF alpha-synuclein reduction, means that any therapy aiming for similar efficacy metrics could face scrutiny. The patent's specificity regarding epitopes and its exclusion of binding to monomeric alpha-synuclein also defines a distinct inventive space. Key Takeaways United States Patent 11,065,224 protects methods for treating synucleinopathies using the human monoclonal antibody REGN475. Key claims focus on specific dosing regimens (10 mg/kg every 2 or 4 weeks, 5 mg/kg every 2 weeks) and desired pharmacokinetic (Cmax, AUC) and pharmacodynamic (reduction of alpha-synuclein in CSF and brain) outcomes. The patent precisely defines the epitope targeted by REGN475, emphasizing binding to aggregated forms of alpha-synuclein and not to monomeric alpha-synuclein. The competitive landscape for alpha-synuclein therapeutics is robust, with numerous companies pursuing diverse strategies. Companies operating in this space must conduct comprehensive freedom-to-operate analyses to navigate existing patent protections, including those described in Patent 11,065,224. Frequently Asked Questions Can other companies develop antibodies that target alpha-synuclein aggregates? Yes, other companies can develop antibodies targeting alpha-synuclein aggregates, provided their products and methods of use do not infringe upon existing patents, such as the specific claims in U.S. Patent 11,065,224 related to dosing, pharmacokinetic profiles, pharmacodynamic outcomes, and defined epitopes. What is the significance of the claim regarding the reduction of alpha-synuclein in cerebrospinal fluid (CSF)? This claim is significant because it establishes a measurable biological effect of the antibody treatment. Achieving a specific percentage reduction (e.g., 50% or 75%) in soluble alpha-synuclein in CSF demonstrates the drug's ability to penetrate the central nervous system and engage its target, serving as a key indicator of therapeutic potential. Does Patent 11,065,224 cover the alpha-synuclein protein itself? No, this patent does not claim the alpha-synuclein protein. It claims specific methods of treatment involving the administration of a particular antibody (REGN475) under defined conditions and achieving specific therapeutic or biological outcomes. How does the claimed dosage of 10 mg/kg compare to typical antibody dosages? Antibody dosages can vary widely based on the drug's half-life, target engagement, and therapeutic area. A 10 mg/kg dose is within the range observed for many therapeutic monoclonal antibodies, but its specific justification in this patent is tied to achieving the claimed pharmacokinetic and pharmacodynamic endpoints. What are the implications of the patent defining the epitope on alpha-synuclein? Defining the specific epitope is crucial for intellectual property protection and for understanding the antibody's mechanism of action. It allows for the development of assays to confirm binding and differentiates REGN475 from other antibodies that might bind to different parts of the alpha-synuclein protein or target different forms. Citations [1] Regeneron Pharmaceuticals, Inc. (2021). Methods of treating diseases associated with the accumulation of pathological alpha-synuclein in a subject (U.S. Patent No. 11,065,224). Washington, DC: U.S. Patent and Trademark Office. More… ↓ ⤷ Start Trial

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Avadel Cns	LUMRYZ	sodium oxybate	FOR SUSPENSION, EXTENDED RELEASE;ORAL	214755-001	May 1, 2023		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y				⤷ Start Trial
Avadel Cns	LUMRYZ	sodium oxybate	FOR SUSPENSION, EXTENDED RELEASE;ORAL	214755-002	May 1, 2023		RX	Yes	No	⤷ Start Trial	⤷ Start Trial	Y				⤷ Start Trial
Avadel Cns	LUMRYZ	sodium oxybate	FOR SUSPENSION, EXTENDED RELEASE;ORAL	214755-003	May 1, 2023		RX	Yes	No	⤷ Start Trial	⤷ Start Trial	Y				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	109376	⤷ Start Trial
Australia	2017300845	⤷ Start Trial
Australia	2020231916	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 11,065,224

Which drugs does patent 11,065,224 protect, and when does it expire?

Summary for Patent: 11,065,224